Author

Timon J Hartmann

Max Planck Institute of Experimental Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:protein structure· 1 Approach:statistical model· 1

Frequent Co-Authors

David EwersiD· 1 shared Doris KrauteriD· 1 shared Klaus‐Armin NaveiD· 1 shared Michael Werner SeredaiD· 1 shared Robert FledrichiD· 1 shared Sandra GoebbelsiD· 1 shared Stefan VolkmanniD· 1 shared Theresa Kungl· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

David EwersORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Inversely proportional myelin growth due to altered Pmp22 gene dosage identifies PI3K/Akt/mTOR signaling as a novel therapeutic target in HNPP

Doris Krauter, David Ewers, Timon J Hartmann, Stefan Volkmann, Theresa Kungl, Robert Fledrich, Sandra Goebbels, Klaus‐Armin Nave, Michael Werner Sereda

This study identifies PI3K/Akt/mTOR signaling as a therapeutic target for HNPP by showing that mTOR inhibitors reduce hypermyelination in HNPP mouse models.

bioRxiv · Nov 8, 2021 · PreprintNeuroscience